版本:
中国

BRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz

June 15 Eli Lilly And Co

* Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors

* Eli Lilly and Co - Lilly has filed a supplemental biologics license application with FDA for Taltz as a treatment of adult patients with active PSA

* Eli Lilly - patients treated with either dosing regimen of Taltz experienced significant improvements compared with placebo in other key secondary measures

* Eli Lilly and Co - submissions to other regulatory agencies around world are expected later in the year for Taltz

* Eli Lilly and Co- serious adverse events and discontinuation rates due to adverse events were not significantly different between treatment groups

* Incidence of treatment-emergent adverse events was greater with Taltz treatment compared with placebo

* Taltz is also in Phase 3 trials for treatment of radiographic and non-radiographic axial spondyloarthritis Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐